- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S5233
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism |
|---|---|
| Other Retinoid Receptor Inhibitors | TTNPB AM580 Tamibarotene UVI 3003 SR 11237 BMS493 Palovarotene CD1530 AR7 CD3254 |
|
In vitro |
DMSO
: 78 mg/mL
(199.2 mM)
Ethanol : 25 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 391.55 | Formula | C26H33NO2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 65646-68-6 | -- | Storage of Stock Solutions |
|
|
| Synonyms | NSC 374551, 4-hydroxy(phenyl)retinamide, 4-HPR, MK-4016 | Smiles | CC1=C(C(CCC1)(C)C)C=CC(=CC=CC(=CC(=O)NC2=CC=C(C=C2)O)C)C | ||
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04234048 | Recruiting | T-cell Lymphoma|Cutaneous/Peripheral T-Cell Lymphoma|Peripheral T-cell Lymphoma|Peripheral T-Cell Lymphoma Not Classified|Primary Cutaneous T-cell Lymphoma|Cutaneous T-Cell Lymphoma Unspecified|Cutaneous T-cell Lymphoma|Follicular T-Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Sézary''s Disease|Mycosis Fungoides |
SciTech Development LLC |
December 18 2023 | Phase 1 |
| NCT06181760 | Completed | Safety and Tolerability |
Island Pharmaceuticals|Beyond Drug Development |
November 22 2023 | Phase 1 |
| NCT01553071 | Terminated | Solid Tumor |
South Plains Oncology Consortium |
November 2016 | Phase 1 |
| NCT02141958 | Completed | Cystic Fibrosis |
Elias Matouk|McGill University Health Centre/Research Institute of the McGill University Health Centre |
April 2014 | Phase 1 |
| NCT01535157 | Terminated | Ovarian Cancer|Cancer of Ovary|Cancer of the Ovary|Ovary Neoplasms|Primary Peritoneal Carcinoma |
South Plains Oncology Consortium |
February 2012 | Phase 1|Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.